Copaxone and Tooth loss - a phase IV clinical study of FDA data

Summary:

Tooth loss is reported as a side effect among people who take Copaxone (glatiramer acetate), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Oxycontin, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Tooth loss when taking Copaxone. It is created by eHealthMe based on reports of 56,345 people who have side effects when taking Copaxone from the FDA, and is updated regularly.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 56,931 Copaxone users. Check the latest studies of Copaxone.

What is Tooth loss?

Tooth loss is found to be associated with 1,095 drugs and 943 conditions by eHealthMe. Check the latest studies of Tooth loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 03, 2026

56,345 people reported to have side effects when taking Copaxone.
Among them, 30 people (0.05%) have Tooth loss.

Among these 30 people:

How long have people been on Copaxone when they have Tooth loss? *

What is the gender of people who have Tooth loss when taking Copaxone? *

female: 75.86 %
male: 24.14 %

What is the age of people who have Tooth loss when taking Copaxone? *

What are other drugs people take besides Copaxone? *

What are other side effects people have besides Tooth loss? *

Tooth Fracture: 5 people, 16.67%
Depression: 5 people, 16.67%
Dental Caries: 5 people, 16.67%
Dyspnea (difficult or laboured breathing): 4 people, 13.33%
Osteomyelitis (infection of bone): 4 people, 13.33%
Urinary Tract Infection: 4 people, 13.33%
Fall: 4 people, 13.33%
Stress And Anxiety: 4 people, 13.33%
Constipation: 4 people, 13.33%
Gait Disturbance: 3 people, 10.00%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 2 people, 6.67%
Constipation: 2 people, 6.67%
Breast Cancer Metastatic: 2 people, 6.67%
Sleep Disorder: 1 person, 3.33%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.33%
Pain In Extremity: 1 person, 3.33%
Pain: 1 person, 3.33%
Muscle Spasms (muscle contraction): 1 person, 3.33%
Metastatic Neoplasm (spreadable cancer tumour): 1 person, 3.33%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and have Tooth loss?

- Check whether Tooth loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Copaxone:

Copaxone (56,931 reports)

Tooth loss treatments and more:

Tooth loss (33,880 reports)

Browse all side effects of Copaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tooth loss:

Tooth loss (1,095 drugs)

Browse all the conditions that are associated with Tooth loss:

Tooth loss (943 conditions)

Related publications that referenced our studies

Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.